MBX Biosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for MBX Biosciences, Inc. (MBX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022
Period EndingDec 2024Dec 2023Dec 2022
Operating Activities
Net Income-61.92-32.56-26.14
Depreciation & Amortization0.240.160.06
Stock Based Compensation5.222.040.31
Change in Working Capital4.60-0.741.29
Change in Accounts Payable3.930.410.67
Change in Other Working Capital0.670.100.62
Other Operating Activities0.110.101.39
Net Cash from Operating Activities-54.68-31.98-23.12
Investing Activities
Capital Expenditures-0.87-0.13-0.44
Purchases of Investments-159.72-63.80-10.97
Sales/Maturities of Investments79.7533.009.25
Net Cash from Investing Activities-160.60-30.93-11.41
Financing Activities
Common Stock Issued174.950.740.03
Other Financing Activities-4.34-0.03-0.46
Net Cash from Financing Activities234.1069.2246.06
Summary
Net Change in Cash18.836.3111.53
Cash at Beginning of Period30.5224.2112.68
Cash at End of Period49.3530.5224.21
Free Cash Flow-55.56-32.11-23.56